ALKERMES | ALKS - Selling And Administration Expenses


ALKERMES reported $171.77M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
J&J USD 6.75B 831M Dec/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.63B 0 Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Otsuka Holdings JPY 254.23B 14.74B Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025